Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25166373 | 0.79 | TDP1 (0.45) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL29064919 | 0.76 | HSP90AB1 (0.45) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL25166327 | 0.76 | TDP1 (0.40) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL3205153 | 0.75 | HSP90AB1 (0.44) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL30295725 | 0.71 | TDP1 (0.36) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL29064935 | 0.71 | TDP1 (0.36) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL1318655 | 0.70 | POLB (0.42) | TDP1 | |
| SCHEMBL19531947 | 0.68 | TDP1 (0.37) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL19531950 | 0.68 | TDP1 (0.37) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL18081247 | 0.67 | PSMB5 (0.37) | TDP1NPC1RAB9APSMB5PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | TDP1 1168/4885NPC1 2169/4885RAB9A 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.